Omeprazole and Gout: Relationship and Management
Omeprazole and other proton pump inhibitors (PPIs) are associated with an increased risk of developing gout, particularly within the first 30 days of treatment, though the evidence is mixed and the absolute risk appears modest.
The Evidence on PPI-Gout Association
The relationship between omeprazole and gout shows conflicting data across studies:
Recent epidemiological evidence suggests a positive association:
- A 2023 population-based case-control study from Taiwan found that esomeprazole increased gout risk (adjusted OR 1.3; 95% CI 1.0-1.6), with the highest risk occurring within 30 days of PPI initiation (adjusted OR 1.7; 95% CI 1.4-1.9) 1
- The risk was particularly elevated in women (adjusted OR 2.2; 95% CI 1.7-2.8) and middle-aged individuals 41-60 years (adjusted OR 2.1; 95% CI 1.7-2.7) 1
- A 2018 study proposed that antacids slow ATP turnover rate, leading to elevated serum uric acid levels 2
However, older evidence contradicts this:
- A 1997 UK cohort study of over 53,000 patients found no material association between current omeprazole use and newly diagnosed gout (age- and sex-adjusted RR 1.1,95% CI 0.5-2.1) 3
Importantly, a 2025 study suggests not all PPIs carry equal risk:
- Lansoprazole users had significantly lower gout risk compared to other PPI users (adjusted HR 0.64; 95% CI 0.56-0.73), potentially due to effects on insulin resistance and adipogenesis 4
Clinical Management Approach
For Patients with Gout Requiring Acid Suppression:
Consider lansoprazole as the preferred PPI when acid suppression is necessary in patients with gout or at high risk for gout, based on the most recent comparative evidence 4.
When NSAIDs Are Prescribed for Acute Gout Flares:
PPIs are explicitly recommended for gastroprotection when NSAIDs are used to treat acute gout attacks. The 2017 EULAR guidelines state: "Recommended first-line options for acute flares are colchicine...and/or an NSAID (plus proton pump inhibitors if appropriate)" 5.
This creates a clinical scenario where the benefit of gastroprotection outweighs theoretical gout risk, particularly since:
- Acute flare treatment is time-limited (days, not chronic use)
- The highest PPI-associated gout risk occurs within 30 days 1
- NSAID-induced GI complications carry significant morbidity
Risk Stratification:
Highest concern for PPI-associated gout risk:
- Women requiring PPI therapy
- Middle-aged patients (41-60 years)
- First 30 days of PPI initiation
- Patients with other gout risk factors (hypertension, obesity, male gender) 3, 1
Practical Algorithm:
If PPI is indicated for appropriate gastroprotection with NSAID gout treatment: Use PPI without hesitation (preferably lansoprazole if available)
If chronic PPI needed in patient with established gout:
- Prioritize lansoprazole over other PPIs 4
- Ensure optimal urate-lowering therapy is in place
- Monitor serum uric acid levels
If chronic PPI needed in patient at high gout risk:
- Consider lansoprazole as first choice
- Address modifiable gout risk factors (weight loss, limit alcohol, avoid high-fructose corn syrup) 6
- Monitor for gout symptoms, especially in first month
If PPI indication is marginal: Reassess necessity, particularly in patients with multiple gout risk factors
Key Caveats
- The absolute risk increase from PPIs appears modest and may be confounded by indication (patients requiring PPIs often have comorbidities that independently increase gout risk)
- The FDA label for omeprazole does not list gout as a known adverse effect 7
- Do not discontinue appropriate PPI therapy solely due to gout concerns—manage both conditions appropriately
- The gastroprotective benefit of PPIs when using NSAIDs for gout flares is well-established and takes precedence